Compare BridgeBio Pharma Inc (BBIO) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Twilio Inc — how do they compare? BridgeBio Pharma Inc trades at $84.87 (market cap $16.46B), while Twilio Inc trades at $220 (market cap $33.06B). The key difference: Twilio Inc is far larger — about 2× BridgeBio Pharma Inc's market cap. Which is the better fit depends on your goals.
| BBIO | TWLO | |
|---|---|---|
Market Cap | $16.46B | $33.06B |
Sector | Health | Technology |
52-Week High | $90.17 | $236.64 |
52-Week Low | $44.81 | $92.44 |
Enterprise Value | $18.02B | $31.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Twilio (TWLO) trades at $218.24, up 1.72% today, showing strong momentum after recent earnings beats. The stock is in a bullish technical trend with support at $212 and resistance at $223. Revenue grew to $5.07B in 2025, with net income turning positive at $33.83M, signaling a successful turnaround. Analyst sentiment is overwhelmingly positive, with 77% recommending Buy and a consensus price target of $215.14. Operating cash flow reached $1.0B, reflecting improved financial health.
Outlook: Twilio's AI-driven communication tools and margin expansion under CEO Khozema Shipchandler support growth, but high valuation multiples (P/E 330.67) pose risks. Competition and execution challenges remain key concerns. The stock offers upside if earnings momentum continues, yet volatility near 52-week highs warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
